Gilead And Arcus’ Latest Update Keeps TIGIT Hopes Afloat

Data Readout On 20 December

 
• By Andrew McConaghie
  
Arcus Biosciences
Arcus and Gilead hope their 'Fc-silent' molecule will have a better safety and efficacy profile than other TIGITs. • Source: Shutterstock

More from Business

More from Scrip